Bottom line: these drugs overpromise and can make medium-term weight gain worse if you stop (which half of people do within a year in real-world data)
For instance, many AD patients display behavioral symptoms such as rest-activity rhythm fragmentation [176], sundowning (characterized by recurring confusion or agitation in the late afternoon or early evening) [177], and disturbances in sleep and wake maintenance [178]
Lillys triple agonist, retatrutide, demonstrated significant reductions in A1C and weight in first Phase 3 trial for treatment of type 2 diabetes
The injectable versus oral peptide comparison is also relevant here, because some researchers transitioning from oral semaglutide may have different GLP-1 receptor adaptation profiles than those coming from injectable formulations
Warning Letters to Telehealth providers marketing GLP-1 compounded On March 3rd, FDA sent multiple sets of warnings to 30 Telehealth companies offering GLP-1s on their websites warning them to refrain from improperly using a brand when they are not the compounder or claiming equivalency to FDA approved drugs